One of the first breast-PDO biobanks was established from HER2-positive, HER2-negative and triple negative breast cancer patients (TNBC), showing an acceptable degree of concordance between the primary tumor and PDO histology [39]. Here, ERBB2 is linked to triple-negative breast carcinoma.